Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387448 · ClinicalTrials.gov registry record · Phase 2
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
A Phase 2 study, sponsored by Goldfinch Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT04387448 is a Phase 2 study that was terminated before completion, run by Goldfinch Bio. The registered enrollment target is 96 participants.
The verdict
NCT04387448, a Phase 2 study, was terminated before completion, sponsored by Goldfinch Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD).
Interventions
- DRUG Placebo
- DRUG GFB-887
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04387448
The ClinicalTrials.gov registry entry for NCT04387448 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldfinch Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04387448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04387448 about?
NCT04387448 is a clinical study titled "A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease". This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD).
What is the current status of trial NCT04387448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2020-07-28. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04387448?
The interventions under investigation include: Placebo (DRUG), GFB-887 (DRUG).
Who is sponsoring clinical trial NCT04387448?
This trial is sponsored by Goldfinch Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.